EGFR and glioma: Antisomatostatin 2 receptor peptide-based targeted delivery of encapsulated 3,3′-diindolylmethane (antitumor compound) nanoparticles prevents the progression of gliomas; this procedure promotes apoptosis and abrogates the activation of the epidermal growth factor receptor pathway in glioma cells [104].